Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases CONCLUSION: Our study suggests that PAK1/2/3 fusions is the oncogenic driver of a subset of porocarcinomas lacking YAP1 … ← Vertebral artery hypoplasia and hemodynamic impairment in transient global amnesia: a case control study Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update →